The partnership will integrate PhaseV's adaptive clinical trial technology with Alimentiv's comprehensive GI CRO services.

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (Upstream: QNTM) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a ...

The luxury-goods company’s shares plunged after it said it was parting ways with its chief executive before the end of his ...

Argentina's award-winning mare Polo Pureza will have her genes, or at least most of them, live on in five genetically edited ...

Eleven officers, including Siva Chaitanya, from across the country attended the training programme which covered advanced GMP topics ...

A team from UNIGE, the Max Planck Institute for Molecular Physiology in Dortmund, and Heinrich Heine University in Düsseldorf ...